Life Sciences & Health Care M&A update: Q4 2018
The Life Science and Health Care industry has historically faced challenges when it pertains to keeping cost low while delivering high-quality health care services. With the advancement of 3D printing in the health care space, stakeholders will be able to drive improved health related services, while reducing costs. Life Sciences & Health Care mergers and acquisitions (M&A) update provides Deloitte Corporate Finance LLC insights and market data analysis that shed light on M&A trends in the Life Sciences and Health Care industry.
How 3D printing can revolutionize health care
Health plans, providers, life sciences companies, and the government are increasingly facing rising costs and inconsistent outcomes. They are working to achieve the triple goal of improving care, improving health, and reducing costs. Advancements in 3D printing technology offers stakeholders across the Life Sciences and Health Care (LSHC) space a triple-pronged approach to help achieve these goals.
3D printing is a process that works by building solid, three-dimensional objects from a digital model, adding materials layer by layer, rather than producing a final product by cutting away excess. 3D printing technologies are driving innovation across the health care continuum, with significant and wide-ranging benefits including:1
- Greater access to health care products and technology2
- Availability of specialized medical devices3
- Improved procedural outcomes4
Key 3D printing M&A value drivers
- Streamlining supply chains: The efficient and scalable benefits of 3D printing technologies can decrease medical costs and enable health care providers to more effectively compete in the marketplace.
- Mass product customization: Harnessing the power of 3D printing technology allows healthcare professionals to produce previously unavailable or outdated medical devices and specialized products.
- Large runway for growth: As the barriers for widespread adoption of 3D printing technologies are lowered and regulations loosened, the global 3D printing market is projected to grow at a compound annual growth rate (CAGR) of 24 percent through 2023.5
This newsletter is a periodic compilation of certain capital markets information.
1 Deloitte Center for Health Solutions (DCHS). Master Protocol Clinical Trial Drug Development Process. October 2018.
- Life sciences & health care M&A update: Q3 2018
- Life sciences & health care M&A update: Q2 2018
- Life sciences & health care M&A update: Q1 2018
- Life sciences & health care M&A update: Q4 2017
- Life sciences & health care M&A update: Q3 2017
- Life sciences & health care M&A update: Q2 2017
- Life sciences & health care M&A update: Q4 2016